Drug intelligence / Profile preview

CD19 t-haNK + nogapendekin alfa inbakicept

Development stage: Unknown
Lead developer: ImmunityBio
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

CD19 t-haNK + nogapendekin alfa inbakicept is a combination immunotherapy consisting of an off-the-shelf, CD19-targeted natural killer (NK) cell therapy and an IL-15 superagonist. CD19 t-haNK is derived from the NK-92 cell line, engineered to express a chimeric antigen receptor (CAR) targeting CD19 and a high-affinity CD16 (V158) receptor to enhance antibody-dependent cellular cytotoxicity (ADCC). Nogapendekin alfa inbakicept (N-803) is an IL-15 superagonist complex designed to promote the proliferation and activation of NK cells and T cells without stimulating regulatory T cells. The combination is primarily being investigated for the treatment of relapsed or refractory CD19-positive B-cell non-Hodgkin lymphomas.

Other names: CD19 t-haNK + N-803CD19 t-haNK + NAI

Targets

CD19 (B lymphocyte antigen CD19)IL-2/15Rβγ (Interleukin-2/interleukin-15 receptor beta/gamma)

Beyond the preview

Go deeper on CD19 t-haNK + nogapendekin alfa inbakicept.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD19 t-haNK + nogapendekin alfa inbakicept.

Explore the full profile